India Rejects Extending Drug Patents In EU, UK Trade Talks

New Delhi : India has communicated its unwillingness to dilute its stance on data, intellectual property and government procurement to the European Union and the United Kingdom as part of ongoing trade agreement talks with them, officials said.

India is firm on its red lines on cross-border data flows as there is no ecommerce policy at present, while any commitments on data exclusivity and patent extensions would impact the manufacturing and distribution of generic medicines, they said.

On government procurement, India plans to stick to its stance to continue to reserve 25% for medium and small enterprises, officials said.

“The digital space and intellectual property rights are evolving areas. The red lines like data are to be kept away,” one of them told ET.

The IPR red line is of data exclusivity, which the EU has been seeking for a long. It is a provision that would hamper production of cheap generic medicines in the country, officials said.

The UK and the EU have sought amendment in India’s Patents Act to allow ‘evergreening’ of patents, especially in the pharmaceuticals sector. Section 3(d) of the Act prohibits the grant of ‘evergreening’ patents, which are additional patents for a drug with no therapeutic benefit and serve only to increase the term of patent monopoly.

“Patent monopolising is a red line for us and that’s clearly conveyed because  we want generics while the EU is strong in patented drugs,” said the official quoted above.

In government procurement, India has stated that it can’t compromise on the comforts given to small and medium enterprises.

Experts said India needs to be cautious about any commitments in services trade leading to cross-border data flows.

“Even if the UK shows flexibility on the digital front, India needs to be careful and not cede grounds in the services chapter,” a trade expert said.

Similarly, any commitments on digital trade will mark a permanent shift in India’s trade policy stance on ecommerce at the World Trade Organisation (WTO) where it is opposed to any binding commitments besides having implications for India’s security.

India has so far refrained from making any international commitments on digital trade in order to protect its policy space to design national digital sector policies in the future including on digital industrialisation.

  • Related Posts

    Cancer cure must not be hostage to Big Pharma

    In recent years, immunotherapy has expanded the limits of cancer treatment. Therapies that harness the body’s immune system to fight malignant cells have improved survival rates in cancers once considered…

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    Pune:- A woman, 34, dia­gnosed with poly­cystic ovary syn­drome, or PCOS, as a teen­ager, saw her first nat­ural men­strual cycle in Feb­ru­ary—six months after start­ing Moun­jaro for weight man­age­ment. This…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Cancer cure must not be hostage to Big Pharma

    Cancer cure must not be hostage to Big Pharma

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

    Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

    Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

    COMT Inhibitors May Fuel Gut Bacteria That Degrade Levodopa In Parkinson’s Patients

    COMT Inhibitors May Fuel Gut Bacteria That Degrade Levodopa In Parkinson’s Patients